Navigation Links
Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplasty's Urgent® PC Neuromodulation System
Date:8/23/2010

MINNEAPOLIS, Aug. 23 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that Noridian Administrative Services, LLC and Palmetto GBA, South Carolina, both regional Medicare carriers, now cover percutaneous, posterior tibial nerve stimulation (PTNS) using the Urgent® PC Neuromodulation System for the treatment of the symptoms of overactive bladder.  Noridian administers benefits for Medicare beneficiaries in North and South Dakota, Montana, Wyoming, Utah and Arizona.  The Palmetto GBA policy covers Medicare beneficiaries in South Carolina.

Both Noridian and Palmetto GBA will cover PTNS therapy for patients who have failed, or demonstrated intolerance to, the standard anticholinergic drug therapy.  Coverage includes an initial course of 12 weekly PTNS treatments, and for those patients who respond to the initial PTNS treatments, additional treatments once every three weeks for up to one year.  Claims for PTNS treatments can be billed electronically using the unlisted CPT code 64999.  In addition, Noridian has indicated that up to three physician consultations to evaluate and manage treatments during the initial course of PTNS therapy will also be reimbursed.

"We are very pleased and excited that these two regional Medicare carriers now cover PTNS treatments using our Urgent PC Neuromodulation System," said David Kaysen, President and CEO of Uroplasty, Inc.  "Both carriers have reviewed our strong clinical data and determined that PTNS treatments should be covered and reimbursed for the beneficiaries within their coverage areas.  We are continuing to actively meet with medical directors of other Medicare carriers and private payers to share with them the strong clinical data and encourage them to cover and reimburse PTNS treatments."

Links to the websites providing details on the coverage policies of the two Medicare carriers are as follows:

For Noridian:

https://www.noridianmedicare.com/provider/updates/docs/PTNS_Coverage_acro.pdf

For Palmetto GBA:  http://www.cms.gov/mcd/viewlcd_pdf.asp?lcd_id=27267&lcd_version=10&contractor_id=19

About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence – symptoms often associated with overactive bladder.

We also offer Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements. For Further Information: Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer

952.426.6140

EVC Group

Doug Sherk (Investors)

415.896.6820

Chris Gale (Media)

646.201.5431
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. Lack of Medicare Part D Coverage for All Medically Necessary Prescriptions Endangers Older Americans and Those with Chronic Diseases and Disabilities
3. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
4. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
5. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
6. Advaxis, Inc Initiation Coverage Review Issued By Scimitar Equity, LLC
7. Online Coverage of International AIDS Conference Includes Daily Webcasts, Podcasts and Interviews
8. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
9. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
10. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
11. WJB Capital Group, Inc. Expands Coverage of Healthcare Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 According to ... for cryotherapy is set to witness a CAGR of 6.5% during ... America will continue to be the leading market for ... ... Suppliers are emphasizing on ensuring affordable and adequate supply of gas ...
(Date:1/19/2017)... Jan. 19, 2017 ViewRay, Inc. (Nasdaq: VRAY) announced ... institution supporting research in Germany , ... treatments at the University Clinic Heidelberg as part of ... MRIdian Linac program will be headed by Medical Director ... radiation oncology at the German Cancer Research Center (DKFZ), ...
(Date:1/19/2017)... BEACH, Florida , January 19, 2017 /PRNewswire/ ... incoming Trump administration appears serious about reducing the ... advancements and innovation in the medical drug industry, ... forge ahead with new clinical trials and development ... Pharma companies forging ahead with recent developments include:  ...
Breaking Medicine Technology:
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Doctor ... announced it attended the January ECRM trade show to continue the marketing and distribution ... vitamin C supplement, known for providing 400 percent better absorption than traditional vitamin C ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Michael and ... Dana Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as ... has not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following ... Chocolate Biscuit” is the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida ... went to school and at 19 years of age, he joined the Navy and got ...
(Date:1/20/2017)... ... ... is God’s Lighthouse”: a moving and colorful collection of prayers that reminds readers ... author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published works ... school and have many different titles,” Gaapf mentions about his different works. “I am ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Next week after ... be repealed by Congressional political games that circumvent health needs of over 30 million. ... capture the human anxieties and needs government public servants were suppose to prioritize. Interviews ...
Breaking Medicine News(10 mins):